You are viewing a preview of...
Neo-T: Autologous Mutant Neoantigen-Specific, TCR-Engineered T Cells For Adoptive Cellular Therapy
A proprietary platform called “Neo-T” allowing the use of mutant neoantigens from an individual’s own cancer cells as a target structure
Selecting appropriate antigens on cancers is critical for development of T cell-based cellular therapies. Because of the enormous number/diversity of cancers it is impossible to clearly identify tumor antigens that can function as targets across different tumor entities and large groups of patients.
Inventors at the University of Chicago have developed a proprietary platform called “Neo-T” allowing the use of mutant neoantigens from an individual’s own cancer cells as a target structure for adoptively transferred T cells. The technology is based on the selection of a suitable pair of T cell receptors (TCRs) that can recognize neoantigens presented by patient MHC molecules ().
To achieve tumor eradication, one of the two TCRs must recognize a neoantigen in
Log in or create a free account to continue reading